Biocon has informed that it has attached a Company Statement on 26th April titled ‘Biocon Biologics and Viatris Receive European Commission Approval for Biosimilar Bevacizumab’. The above information will also be available on the website of the Company at www.biocon.com.
The above information is a part of company’s filings submitted to BSE.